Latest News
GSK secures first global approval for Hibsago in Japan
24 August 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that it has received Japan's first global approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B in adults who have received ...
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
24 August 2026 - South Korean pharmaceutical company Hanmi Pharm Co Ltd announced on Monday that it has entered into an exclusive licensing agreement with Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), for the development, manu...
Pulnovo Medical commences enrolment in PULSE-LHD IDE clinical trial
24 August 2026 - Medical technology company Pulnovo Medical announced on Sunday the enrolment of the first two patients in its PULSE-LHD clinical trial, conducted under a US Food and Drug Administration (FDA) Investigational Device Exemption (IDE), a...
Rznomics joins Lilly Gateway Labs to accelerate RNA therapeutics
24 August 2026 - Rznomics Inc (KOSDAQ:476830), a South Korea-based biopharmaceutical company specialising in the development of RNA-based gene therapies, announced on Sunday that it is joining Lilly Gateway Labs (LGL) in San Diego, California.Lilly G...
Anbogen Therapeutics enters collaborative research agreement with University of Tokyo for ABT-301 evaluation across multiple tumour types
24 August 2026 - Anbogen Therapeutics Inc (TPEx:7784), a Taiwan-based, clinical-stage precision oncology company, announced on Sunday that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduat...